Table 1.
Baseline characteristics
| Placebo (n=129) | Crossover denosumab (n=129) | Long-term denosumab (n=150) | ||
|---|---|---|---|---|
| FREEDOM baseline | OLE baseline | FREEDOM baseline | OLE baseline | |
| Age (years), mean ± SD | 72.1 ± 5.3 | 75.2 ± 5.3 | 72.8 ± 4.9 | 75.9 ± 4.9 |
| Body mass index (kg/m2), mean ± SD | 24.9 ± 4.2a | 25.1 ± 4.3 | 25.2 ± 4.2 | 25.0 ± 4.5 |
| Race, n (%) | ||||
| White or Caucasian | 111 (86.0) | 111 (86.0) | 132 (88.0) | 132 (88.0) |
| Hispanic or Latino | 16 (12.4) | 16 (12.4) | 18 (12.0) | 18 (12.0) |
| Other | 2 (1.6) | 2 (1.6) | 0 | 0 |
| Prevalent vertebral fracture, n (%) | 24 (18.6) | 28 (21.7) | 38 (25.3) | 40 (26.7) |
| LS BMD T-score, mean ± SD | −2.81 ± 0.60 | −2.81 ± 0.65 | −2.75 ± 0.81b | −2.10 ± 0.82c |
| TBSTT, mean ± SD | 1.033 ± 0.076a | 1.018 ± 0.073d | 1.029 ± 0.080e | 1.060 ± 0.080e |
BMD, bone mineral density; LS, lumbar spine; SD, standard deviation; TBS, trabecular bone score; TBSTT, tissue thickness–adjusted TBS
an=125; bn=149; cn=148; dn=124; en=142; n = number of patients with observed data